Lọc tín hiệu
DP1

DP1

Central Pharmaceutical CPC1
PharmaceuticalsUPCOM
Same sector:AGPAMPBCHBCPBIOCDPCNCDANDBDDBM
28.400
−2,07%
2026-10-19

Fundamental Analysis

93 / 100ARubric: Manufacturing
Quarterly resultsRelative Valuation
CriterionLatest Q EPS growth (YoY)Avg EPS growth, last 3 (YoY)Quarters with EPS growthRevenue growth (YoY)Gross margin change (pp, YoY)Net margin change (pp, YoY)Return on Equity (TTM)Financial health (Debt/Equity)Valuation (P/E vs 5-yr median)Revenue (bn)Rev YoYNPAT (bn)NPAT YoYP/E5-Year Median P/EP/E vs. 5-Year Median
Value+97.7%+48.1%2 / 3+23.6%+0.76 pp+2.46 pp+21.3%0.714.73677+23,6%44,4+97,7%4.737.15−33,8%
Pts1212812812121212
Valuation annotation:Price: 28.400 (close price on 2026-10-19)EPS (TTM): 6.001

Financial charts

1.Revenue & growth

VND bn677Q2/26

1.Revenue & growth

VND bn677Q2/26

2.Profit & growth

VND bn41,4Q2/26

3.Profit mix (Penman)

VND bn156Q2/26

4.Margins & cost structure

%12.6%Q2/26

5.Returns & cash cycle

% · days9.7%Q2/26

6.Earnings quality & cash

VND bn40,1Q2/26

7.Asset structure

VND bn1.788Q2/26

8.Funding & debt health

VND bn · times1.788Q2/26

9.Revenue backlog

VND bn9,83Q2/26

10.Valuation

times · %4,8×Q2/26

11.EPS growth & dilution warning (CANSLIM)

VND per share; growth in %1.973Q2/26
Adjusted EPS growth, latest quarter
84.3%
Average adjusted EPS growth, 3 quarters
43.6%
Quarters at 25%+ growth
2/3
Share dilution rate, 1 year
0.0%

Source: vnstockData through Q2/26